Virology Fellows HIV/AIDS
The Bristol-Myers Squibb Virology Fellows Research Training Program is currently accepting research proposals from M.D. Fellows to further advance the science and knowledge as it relates to the care of individuals infected with HIV/AIDS and support the development of future clinical researchers. A grant of up to $30,000 will be awarded to support research-related expenses for a one-year period.
The following research topics will be considered:
RFP-US-12-AI266-001
- Further evaluation on the optimal time to initiate antiretroviral therapy in HIV-infected patients
- Identification and evaluation of HIV-related chronic inflammatory changes and impact on long term outcomes
- Effect of HIV minority drug-resistant variants on virologic outcomes
- Determination of the clinical and economic outcomes of regimen simplicity with antiretrovirals
- Use of antiretrovirals in combination with newer agents including novel treatment paradigms (such as nucleoside-sparing regimens)
- Antiretroviral regimen sequencing
- Long term efficacy, safety and tolerability profile of antiretroviral agents including metabolic outcomes, resistance, and cardiovascular risk
- Efficacy and safety of antiretrovirals in special populations (e.g. women, racial or ethnic minorities, pediatrics, and older patients, HCV coinfection)
Chronic Hepatitis B (CHB)
The Bristol-Myers Squibb Virology Fellows Research Training Program is currently accepting research proposals from M.D. Fellows to further advance the science and knowledge as it relates to the care of individuals infected with Chronic Hepatitis B (CHB) and support the development of future clinical researchers. A grant of up to $30,000 will be awarded to support research-related expenses for a one-year period.
The following research topics will be considered:
RFP-US-12-AI463-002
- Awareness of and adherence to treatment guidelines, and their impact on disease outcomes
- Long term efficacy, resistance, and safety of antivirals for CHB disease and its impact on disease outcomes
- Correlation of therapeutic endpoints (virologic, serologic, and histologic) on disease progression and outcomes
- Effect of initial antiviral therapy with one agent on response to subsequent therapy with other antivirals
- Efficacy and safety of antivirals in special populations of CHB patients (such as immunotolerant, antiviral experienced with antiviral resistance, or decompensated liver disease)